Aurobindo Pharma Limited (AUROPHARMA.BO)
BSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹1,633.00 (+2.70%) as of
Key statistics
- Market cap
- 949.89B
- P/E (TTM)
- 27.73
- Forward P/E
- 21.79
- EPS (TTM)
- 58.89
- Dividend yield
- 0.33%
- 52-week range
- 994.35 – 1,634.20
- Beta
- 0.05
- Revenue (TTM)
- 325.14B
- Profit margin
- 10.53%
- Analyst target
- ₹1,318.62
- Volume
- 224.99k
About Aurobindo Pharma Limited
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Hyderabad, India
- Employees
- 27,707
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.